0P0000ZP87.F closed at 33.71 EUR on October 29, its highest level in a year, after gaining 3.9% over five sessions while the S&P 500 fell 1.7% — a 10.3 percentage point outperformance over 50 days that reflects the fund's continued leadership within healthcare equities. The long-term uptrend remains intact, the daily and weekly trends are aligned, and the fund holds comfortably above its 50-day average at 30.6 EUR. The stance stays bullish with medium conviction, though the RSI reading of 82.6 means the near-term move has been aggressive and leaves less room for error on the next pullback.
Why it matters
The healthcare sector has been navigating a complex backdrop since mid-October. Regulatory scrutiny around pharmaceutical pricing remains a persistent theme: on October 13, the FTC and seven states moved to hold Martin Shkreli in contempt for allegedly influencing biopharma stocks in violation of a court-ordered industry ban, according to The Guardian and Morningstar. The move drew attention to how individual actors can move sentiment in smaller biopharma names, though the direct impact on a diversified healthcare ETF is limited. Separately, EssilorLuxottica's smartglasses revenue figures, reported by The Wall Street Journal on October 21, highlighted the growing intersection between healthcare and consumer technology — a theme that may be contributing to the sector's relative strength.
Over the five days ending October 30, 0P0000ZP87.F gained 3.88% against a 1.73% decline in the S&P 500, meaning the fund's move was entirely its own — the sector or individual holdings within the basket drove the outperformance rather than a rising market lifting all boats. The one-month return of 11.5% versus SPY's negative 2.3% over the same span underscores how healthcare has decoupled from the broader equity market in recent weeks. This matters because it suggests the thesis driving the fund — whatever it is — has independent momentum, not just beta.
The broader market backdrop adds texture. CNBC reported that Jim Cramer expects continued volatility as tech earnings and midterms loom, with the Nasdaq falling 2.9% on Friday alone after a 2.3% gain through Wednesday. Meanwhile, a London strategist warned via Bloomberg Business that AI-driven equity valuations face a potential correction. If that correction broadens, healthcare's relative resilience could be tested — the sector's defensive characteristics may attract flows, or it could be dragged if the selling is indiscriminate.
What the evidence says
The long-term thesis is intact. The fund trades above its 40-week average, above its 200-day average at 29.3 EUR, and sits just 0.83 EUR below its all-time high of 33.71 EUR set on October 29. The six-month return of 22.6% and year-to-date return of 12.1% compare favorably to SPY's 10.3% year-to-date gain, confirming that the fund has been a consistent outperformer over the intermediate term. There is no evidence the trend is broken; the structure remains firmly bullish on the weekly chart.
Over the next two to six weeks, the balance of evidence leans positive. The daily trend runs with the weekly uptrend, and the fund leads the S&P 500 by 10.3% over 50 days — a meaningful divergence that shows buyers are choosing healthcare names over the broad market. The stance is bullish with medium conviction because two of four conviction points are met: the trend alignment and the relative strength versus SPY. The reading is not higher because the RSI at 82.6 is extended, meaning the move has been sharp and a pullback or consolidation is plausible before the next leg higher. The strongest case against the bullish reading is that the fund is up 11.5% in one month and 22.6% in six months — rapid gains that have compressed the distance to resistance and leave the fund vulnerable to profit-taking if the market environment deteriorates. That risk is real, but it does not change the structural picture as long as the fund holds above 30.6 EUR.
Levels that matter
The fund holds above its 50-day average at 30.6 EUR, which is the structural floor. As long as price remains above this level, the short-term uptrend is intact. The first crack in the structure would appear on a sustained move below 30.6 EUR; a close below 30.43 EUR, a swing zone, would signal that the momentum has shifted and the trend is under pressure. Below that, the 200-day average at 29.3 EUR and the round number at 30.0 EUR represent deeper support. The long-term uptrend would end on a weekly close below 30.43 EUR.
The breakout level is 35.0 EUR on a daily close with volume above the 20-day average. From 35.0 EUR, the math gives a target of 40.0 EUR — a round number — with a stop at 30.52 EUR (the 50-day average minus a quarter of the 14-day ATR of 0.32 EUR). The reward-to-risk from the breakout level is 1.1 to 1. That does not reach the 3 to 1 threshold that would make a breakout trade compelling on its own terms. To change that math, the target would need to move higher or the stop would need to tighten — neither of which is present in the current structure. The map is clear: 35.0 EUR is the gate, 40.0 EUR is the objective, and 30.52 EUR is where the trade would be wrong.
What would change the picture
The picture would shift on a weekly close below 30.43 EUR, a swing zone that represents the lower boundary of the current consolidation range. That rule is the same as what would end the trend. The one non-price fact that could change the reading is a meaningful deterioration in the healthcare sector's relative strength — if the sector ETF or leading names within the basket begin to lag SPY materially, the fund's leadership thesis would be in question regardless of where the price sits relative to moving averages.
What to watch
- Healthcare sector earnings from component companies over the coming weeks, which could shift sentiment within the basket
- The broader market's response to tech earnings and the midterm election results, as healthcare has shown it can decouple but may not be immune to a severe S&P 500 decline
- The AI trade debate — if the strategist's warning from Bloomberg Business gains traction, defensive sectors like healthcare could see increased demand
- Volume on any move toward 35.0 EUR — a breakout requires participation above the 20-day average